Mimedx (MDXG) Net Margin (2011 - 2026)

Mimedx (MDXG) posted Net Margin of 23.06% for Q2 2026, down 25.24% sequentially from 18.41% in Q1 2026.

Mimedx (MDXG) Net Margin (2011 - 2026) Analysis & Trends

Mimedx has reported Net Margin for 15 years, with the latest figure at 23.06% in Q2 2026.

Quarterly Net Margin changed N/A year-over-year to 23.06% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 7.24% (down 1145.0% YoY) and the FY2025 annual result came in at 11.6%, down 43.0% from the prior year.
Net Margin declined to 23.06% in Q2 2026 per MDXG's latest filing, from 18.41% in the prior quarter.
Over five years, Net Margin peaked at 51.63% in Q4 2023 and troughed at 23.06% in Q2 2026.
A 4-year average of 2.01% and a median of 8.33% in 2023 frame the typical range for Net Margin.
The sharpest annual moves came in 2023 and 2024: Net Margin soared 4069 bps in 2023, then plunged 4362 bps in 2024.
Over 4 years, Net Margin stood at 10.94% in 2022, then soared by 372 bps to 51.63% in 2023, then tumbled by 84 bps to 8.01% in 2024, then tumbled by 388 bps to 23.06% in 2026.
According to Business Quant data, Net Margin over the past three periods registered 23.06%, 18.41%, and 8.01% for Q2 2026, Q1 2026, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.23%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	30.33%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	13.90%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	30.98%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	12.09%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	12.74%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-3.12%
10	Mimedx	622.24 Mn	486.40 Mn	44.38 Mn	-23.06%

Download Data